These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 31634532)

  • 1. Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.
    Siddiqui MS; Van Natta ML; Connelly MA; Vuppalanchi R; Neuschwander-Tetri BA; Tonascia J; Guy C; Loomba R; Dasarathy S; Wattacheril J; Chalasani N; Sanyal AJ;
    J Hepatol; 2020 Jan; 72(1):25-33. PubMed ID: 31634532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
    Pockros PJ; Fuchs M; Freilich B; Schiff E; Kohli A; Lawitz EJ; Hellstern PA; Owens-Grillo J; Van Biene C; Shringarpure R; MacConell L; Shapiro D; Cohen DE
    Liver Int; 2019 Nov; 39(11):2082-2093. PubMed ID: 31402538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers.
    Pencek R; Marmon T; Roth JD; Liberman A; Hooshmand-Rad R; Young MA
    Diabetes Obes Metab; 2016 Sep; 18(9):936-40. PubMed ID: 27109453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
    Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
    Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.
    Hameed B; Terrault NA; Gill RM; Loomba R; Chalasani N; Hoofnagle JH; Van Natta ML;
    Aliment Pharmacol Ther; 2018 Mar; 47(5):645-656. PubMed ID: 29333665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
    Neuschwander-Tetri BA; Loomba R; Sanyal AJ; Lavine JE; Van Natta ML; Abdelmalek MF; Chalasani N; Dasarathy S; Diehl AM; Hameed B; Kowdley KV; McCullough A; Terrault N; Clark JM; Tonascia J; Brunt EM; Kleiner DE; Doo E;
    Lancet; 2015 Mar; 385(9972):956-65. PubMed ID: 25468160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
    Rinella ME; Dufour JF; Anstee QM; Goodman Z; Younossi Z; Harrison SA; Loomba R; Sanyal AJ; Bonacci M; Trylesinski A; Natha M; Shringarpure R; Granston T; Venugopal A; Ratziu V
    J Hepatol; 2022 Mar; 76(3):536-548. PubMed ID: 34793868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obeticholic acid-a new therapy in PBC and NASH.
    Chapman RW; Lynch KD
    Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.
    Rinella ME; Trotter JF; Abdelmalek MF; Paredes AH; Connelly MA; Jaros MJ; Ling L; Rossi SJ; DePaoli AM; Harrison SA
    J Hepatol; 2019 Apr; 70(4):735-744. PubMed ID: 30529590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
    Briand F; Brousseau E; Quinsat M; Burcelin R; Sulpice T
    Eur J Pharmacol; 2018 Jan; 818():449-456. PubMed ID: 29155143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect and safety of obeticholic acid for patients with nonalcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
    Zhao J; Li B; Zhang K; Zhu Z
    Medicine (Baltimore); 2024 Feb; 103(7):e37271. PubMed ID: 38363900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein subclass metabolism in nonalcoholic steatohepatitis.
    Männistö VT; Simonen M; Soininen P; Tiainen M; Kangas AJ; Kaminska D; Venesmaa S; Käkelä P; Kärjä V; Gylling H; Ala-Korpela M; Pihlajamäki J
    J Lipid Res; 2014 Dec; 55(12):2676-84. PubMed ID: 25344588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.
    Makri E; Cholongitas E; Tziomalos K
    World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
    Al-Dury S; Wahlström A; Panzitt K; Thorell A; Ståhlman M; Trauner M; Fickert P; Bäckhed F; Fändriks L; Wagner M; Marschall HU
    J Hepatol; 2019 Nov; 71(5):986-991. PubMed ID: 31254596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy.
    Koren MJ; Kereiakes D; Pourfarzib R; Winegar D; Banerjee P; Hamon S; Hanotin C; McKenney JM
    J Am Heart Assoc; 2015 Nov; 4(11):. PubMed ID: 26586732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
    Loomba R; Sanyal AJ; Kowdley KV; Terrault N; Chalasani NP; Abdelmalek MF; McCullough AJ; Shringarpure R; Ferguson B; Lee L; Chen J; Liberman A; Shapiro D; Neuschwander-Tetri BA
    Gastroenterology; 2019 Jan; 156(1):88-95.e5. PubMed ID: 30222962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
    J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
    Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ
    J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colesevelam improved lipoprotein particle subclasses in patients with prediabetes and primary hyperlipidaemia.
    Goldberg RB; Rosenson RS; Hernandez-Triana E; Misir S; Jones MR
    Diab Vasc Dis Res; 2013 May; 10(3):256-62. PubMed ID: 23152373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.